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Progression of nephropathy in type 2 diabetic patients.
Background. Nephropathy in type 2 diabetes is the single
most common cause of end-stage renal disease (ESRD), but
the decline in kidney function varies considerably between in-
dividuals, and determinants of renal function loss, early in the
course of renal disease, have not been clearly identified.
Methods. In a prospective observational study, we fol-
lowed 227 (60 female) Caucasian type 2 diabetic patients with
nephropathy for 6.5 (range 3 to 17) years from a baseline
glomerular filtration rate (GFR) of 83 (SD30) mL/min/1.73m2
with 7 (range 3 to 22) measurements of GFR (51Cr-EDTA) per
patient. We evaluated determinants of (1) rate of decline in
GFR, (2) risk of doubling in serum creatinine or ESRD, and
(3) mortality using potential risk factors at baseline and during
follow-up.
Results. The mean (SD) rate of decline in GFR was 5.2 (4.1)
mL/min/year. In multivariate regression analysis, higher base-
line albuminuria, systolic blood pressure (SBP), hemoglobin
A1c, GFR, age, and degree of diabetic retinopathy were sig-
nificantly associated with increased rate of decline in GFR
(R2 adj 0.24). During follow-up, elevated mean albuminuria, SBP,
hemoglobin A1c, and lower hemoglobin, heavy smoking, and
presence of diabetic retinopathy were significantly associated
with increased decline in GFR (R2 adj 0.26). During follow-up,
63 patients had a doubling in serum creatinine or developed
ESRD, and 79 patients died, primarily due to cardiovascular
disease. In Cox regression analysis, higher baseline albumin-
uria, hemoglobin A1c, and SBP, together with lower GFR and
hemoglobin, were significantly associated with shorter time to
doubling of serum creatinine or ESRD. Higher baseline albu-
minuria, hemoglobin A1c, SBP, and age were significantly asso-
ciated with increased mortality.
Conclusion. Our long-term prospective study of type 2 dia-
betic patients with nephropathy has revealed several modifiable
risk factors of enhanced progression in kidney disease and in-
creased mortality.
Diabetic nephropathy develops in approximately 40%
of all type 2 diabetic patients and is characterized by per-
Key words: type 2 diabetes, nephropathy, progression of renal disease,
risk factors.
Received for publication February 12, 2004
and in revised form April 26, 2004
Accepted for publication May 13, 2004
C© 2004 by the International Society of Nephrology
sistent albuminuria, elevated blood pressure, and a pro-
gressive decline in kidney function leading toward end-
stage renal disease (ESRD). In addition, these patients
have a high risk of cardiovascular disease, which further
increases with deteriorating renal function [1].
In the past, diabetic renal disease in type 2 patients
was viewed as a rather benign condition in comparison
with type 1 diabetes [2]. However, it has become evident
that type 2 diabetes constitutes the single most frequent
cause of ESRD in the Western world, and the world-wide
prevalence is anticipated to increase considerably due to
the epidemic growth in the number of patients developing
type 2 diabetes [1]. Additionally, type 2 diabetes occurs
more frequently at a younger age, and because these in-
dividuals live longer with diabetes, a higher percentage
may be expected to develop diabetic renal disease and
ESRD.
In both type 1 and type 2 diabetic patients with
nephropathy, a large interindividual variation in the rate
of decline in glomerular filtration rate (GFR) has been
reported [3–10]. This highlights the need for identifica-
tion of risk factors for loss of renal function early in the
course of nephropathy. The identification of risk factors
influencing the long-term prognosis is important for the
creation of new powerful treatment modalities impeding
the development of ESRD. In type 1 diabetic patients
with nephropathy, several factors associated with an
increased rate of decline in renal function have been iden-
tified in a large prospective study [3]. In type 2 diabetic pa-
tients with nephropathy, data on the early course of renal
disease come from observational studies of limited sam-
ple size [5–7, 9, 10] and studies of specific ethnic groups
at high risk of diabetes and its complications (Pima In-
dians and Asians) [8, 11, 12]. Baseline risk factors for
the composite end point of doubling of serum creatinine
or ESRD have been evaluated in proteinuric type 2 dia-
betic patients with impaired renal function participating
in a study documenting the renoprotective capacity of an
angiotensin II receptor blocker during a follow-up pe-
riod of 3.4 years [13]. However, there are no large studies
with prolonged follow-up evaluating risk factors for pro-
gression in renal disease by applying direct measurement
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of GFR repeated regularly over time. Furthermore, fac-
tors linked to mortality have not been evaluated in type
2 diabetic patients with nephropathy.
The aim of our long-term prospective observational
study carried out early in the course of renal disease
was to evaluate potential risk factors associated with en-
hanced loss of renal function, and all-cause mortality in a
large consecutive cohort of albuminuric Caucasian type
2 diabetic patients.
Patients
Since 1983, all patients with diabetes and persistent
macroalbuminuria (albuminuria ≥300 mg/24 hr in at
least two out of three consecutive 24-hour urine collec-
tions) have had their kidney function monitored with one
yearly determination of GFR at Steno Diabetes Center in
Gentofte, Denmark. The data is kept in a registry which
included 411 Caucasian type 2 diabetic patients with
persistent macroalbuminuria. A total of 45 patients were
excluded from the present study due to clinical or labora-
tory evidence of nondiabetic renal disease. Among the re-
maining 366 type 2 diabetic patients with nephropathy we
included in the present study all patients who had at least
three years of follow-up, at least three measurements of
GFR, and who had no clinical or laboratory evidence
of nondiabetic nephropathy or urinary tract disease
(N = 227). These 227 patients were followed until death
or 2003, and determinants of renal function loss and mor-
tality were evaluated in these patients. The remaining 139
patients had less than three years of follow-up on renal
function, and were excluded from the analysis of determi-
nants of renal function loss. However, these 139 patients
were included together with the above-mentioned 227
patients in an additional analysis of baseline predictors
of mortality.
Type 2 diabetes was diagnosed in patients treated by
diet alone or by diet combined with oral hypoglycemic
agents, in patients treated with insulin when body mass
index (BMI) was above normal (≥25 kg/m2 in women,
≥27 kg/m2 in men) at the time of diagnosis and diabetes
onset was after the age of 40 years, or in patients treated
with insulin when BMI was normal and a glucagon-
stimulated C-peptide value was equal to or above
0.60 pmol/mL.
During follow-up, patients were seen at Steno Dia-
betes Center for routine visits approximately three to four
times a year. Body weight, postprandial blood glucose,
hemoglobin A1c, blood pressure, and 24-hour urinary
albumin excretion were determined at each visit, GFR,
serum creatinine, and hemoglobin were determined once
a year, and cholesterol was determined at least every sec-
ond year. No sodium or protein restriction was applied
during the study. During follow-up, the treatment goal
for hemoglobin A1c was 7.5%, as recommended by the
Danish Medical Association. Arterial hypertension was
diagnosed and treated according to the World Health Or-
ganization’s criteria (≥160/95 mm Hg) until 1995, and
thereafter according to the American Diabetes Associa-
tions criteria (≥140/90 mm Hg) [14]. Until 2001, no spe-
cific class of antihypertensive agents was recommended.
The most commonly prescribed agents included diuret-
ics, angiotensin-converting enzyme (ACE) inhibitors, cal-
cium channel blockers, and beta blockers. After 2001,
agents blocking the renin-angiotensin-system were rec-
ommended as initial drugs of choice [15–17]. Low-dose
aspirin and statins were not used systematically in type
2 diabetic patients with macroalbuminuria until 2002 at
Steno Diabetes Center.
Methods
GFR was measured after a single intravenous injection
of 51Cr-EDTA (3.7 MBq) at 08.30 a.m. by following the
plasma clearance of the tracer for 4 hours [18]. The results
were standardized for 1.73m2 body surface area. The sur-
face area calculated at the initial GFR measurement was
used to standardize all subsequent GFR measurements
for 1.73m2 body surface area. The mean intra-individual
day-to-day coefficient of variation in GFR is 4% in our
laboratory.
Diabetic retinopathy was assessed by direct ophthal-
moscopy until 1993, and thereafter by fundus photog-
raphy, both after pupillary dilatation. The degree of
retinopathy was classified as nil, simplex, or proliferative.
Diabetic maculopathy was graded as simplex retinopathy.
The method used for measurement of hemoglobin A1c
from venous blood samples has changed over the years:
from 1983 to 1988, high-performance liquid chromatogra-
phy (HPLC) ion exchange and isoelectric focusing were
used [19]. These methods have a normal range of 4.1% to
6.1% and 4.1% to 6.4%. From 1989, hemoglobin A1c was
measured with HPLC (Bio-Rad Diamat; Bio-Rad, Rich-
mond, CA, USA) with a normal range of 4.1% to 6.4%.
The correlation between this method and the two previ-
ous methods were as follows: r = 0.983 (N = 194) and
r = 0.931 (N = 119), respectively. Finally, from 1994, an-
other HPLC-based method was used (Bio-Rad Variant;
Bio-Rad). The normal range remained unchanged (4.1%
to 6.4%), and the coefficient of correlation between the
latter and present method was r = 0.993 (N = 161).
Serum creatinine was measured using a reaction
rate kinetic technique eliminating pseudocreatinine [20].
Serum cholesterol and hemoglobin were measured with
standard laboratory techniques that were unchanged dur-
ing the study.
Albuminuria was quantitated using radioimmunoassay
from 1983 to 1990 (sensitivity 0.5 mg/L, coefficient of vari-
ation 9%) [21], and from 1990 to 1997 by enzyme im-
munoassay (sensitivity 1.1 mg/L, coefficient of variation
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8%) [22]. A close correlation between radioimmunoas-
say and enzyme immunoassay (r = 0.99) was documented
before changing the methods. From 1997, the DAKO Tur-
bidimetric method (Carpinteria, CA, USA) was used to
measure urinary albumin excretion rate. This method is
closely correlated with enzyme immunoassay (r = 0.99)
and has a coefficient of variation of 5%.
Blood pressure was measured in the sitting position
after approximately 5 to 10 minutes rest with a standard
mercury sphygmomanometer using an appropriate cuff
size.
Smoking history was assessed from patient’s records.
At baseline, patients were classified as smokers if they
smoked more than one cigarette per day, and as heavy
smokers when smoking 20 cigarettes or more per day.
During follow-up patients were classified as smokers
when smoking one or more cigarette per day for more
than 50% of the follow-up period, and as heavy smokers
if they smoked 20 cigarettes per day for more than 50%
of the follow-up period.
ESRD was defined as the need for dialysis or renal
transplantation and doubling of serum creatinine as an
increase of 100%, and to at least 177 lmol/L, as suggested
previously [23].
In all patients included in the study, we obtained infor-
mation on survival status/date of death in 2003 from the
Danish registry of death. Among the 227 patients with
at least three years of follow-up on renal function, death
certificates were obtained to establish the cause of death.
In patients who died with ESRD, the cause of death was
coded as ESRD independent of the cause of death on the
death certificate.
Statistical analysis
Values are expressed as mean (SD) unless otherwise
stated. Albuminuria was logarithmically transformed be-
fore analysis because of the positively skewed distribu-
tion, and is given as geometric mean (95% CI). Mean
values during follow-up of albuminuria, systemic blood
pressure, hemoglobin A1c, hemoglobin, and serum
cholesterol were calculated as the mean of yearly
averages.
Linear regression analysis (least squares method) was
used to determine the rate of decline in GFR for each pa-
tient, using all measured GFR values during follow-up.
Multiple linear regression models using backward selec-
tion was performed to evaluate the impact of variables
at baseline and during follow-up on the rate of decline
in GFR. The validity of the regression analysis was con-
firmed by demonstrating a normal distribution (with a
mean of zero) of the residuals.
Cox proportional hazards regression model with back-
ward selection of baseline variables were used to predict
time from inclusion in the study until doubling in base-
line creatinine or ESRD and time to death. Results are
expressed as rate ratio with 95% confidence interval. The
proportional hazard assumption was assessed by scatter-
plots of the partial residuals of the covariates and time to
event. Once the full regression model for the combined
end point of doubling of serum creatinine or development
of ESRD was determined, each significant risk factor in
the model was divided into tertiles, and the cumulative in-
cidence of doubling of serum creatinine or development
of ESRD were plotted using Kaplan-Meier curves.
Unpaired Student t test was used to compare continu-
ous variables.
P values < 0.05 (two-sided) were considered signifi-
cant.
All calculations were performed using SPSS 12.0
(SPSS, Chicago, IL, USA).
RESULTS
Baseline characteristics of the 227 (60 female) type 2
diabetic patients with nephropathy are shown in Table 1.
At baseline, systemic blood pressure was 158 (19)/86 (10)
mm Hg, albuminuria 726 (122 to 4319) mg/24-h, and
hemoglobin A1c 8.8 (1.6)%. Renal function was generally
well preserved, with a GFR of 83 (30) mL/min/1.73m2,
and only six patients had a GFR below 30 mL/min/1.73m2.
Renal function was evaluated over a median (range)
period of 6.5 (3 to 17) years, with 7 (3 to 22) GFR deter-
minations per patient. During follow-up, the mean (SD)
rate of decline in GFR was 5.2 (4.1) mL/min/year, sys-
temic blood pressure 154(15)/82 (7) mm Hg, albuminuria
581 (70 to 4775) mg/24-h, hemoglobin A1c 8.9 (1.3)%,
serum cholesterol 5.7 (1.2) mmol/L, hemoglobin 8.4 (1.0)
mmol/L, and body mass index 30.5 (5.3). At the end of
follow-up, the mean (SD) number of antihypertensive
agents prescribed per patient was 2.5 (1.1).
Determinants of rate of decline in GFR
Baseline predictors of the rate of decline in GFR were
evaluated in multivariate linear regression analysis, which
revealed that higher baseline values of albuminuria, sys-
tolic blood pressure, hemoglobin A1c, GFR, and age,
together with increasing severity of diabetic retinopa-
thy (nil/simplex/proliferative) were significantly associ-
ated with an increased rate of decline in GFR (Table 2).
Gender, known duration of diabetes or nephropathy,
diastolic blood pressures, pulse pressure, BMI, smok-
ing, heavy smoking, serum cholesterol, or hemoglobin
had no statistically significant impact on the rate of de-
cline in GFR and were excluded from the final model.
Figure 1 illustrates the unadjusted (univariate) and ad-
justed (multivariate) impact on the rate of decline in
GFR of each of the six baseline variables, which were
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Table 1. Baseline characteristics of 227 type 2 diabetic patients with
nephropathy followed for 6.5 years
Total
N = 227
Age years 57 (8)
Male gender N (%) 167 (74)
Known duration of diabetes yearsa 11 (0 to 32)
Known duration of nephropathy yearsa 1 (0 to 11)
Body mass index kg/m2 30.0 (5.3)
Diabetic retinopathy N (%)
Nil 68 (30)
Simplex 112 (49)
Proliferative 47 (21)
Smoking N (%)
None smokers 146 (64)
≥1 and <20 cigarettes per day 38 (17)
≥20 cigarettes per day 43 (19)
History of cardiovascular disease N (%)
Stroke 26 (12)
Myocardial infarction 22 (10)
Coronary-artery-bypass-graft-intervention or 9 (4)
percutanous-coronary-intervention
Amputations 18 (8)
Surgical intervention for peripheral ischemia 4 (2)
Glucose-lowering treatment N (%)
Diet alone 15 (7)
Oral hypoglycemic agents 98 (43)
Insulin 80 (35)
Oral hypoglycemic agents and insulin 34 (15)
Antihypertensive agents per patient N 1.6 (1.1)
Type of antihypertensive medication N (%)
ACE inhibitor 111 (49)
Angiotensin II receptor blocker 11 (5)
Calcium channel blocker 52 (23)
Beta-blocker 34 (15)
Diuretic 153 (67)
Other 8 (4)
GFR mL/min/1.73m2 83 (30)
Creatinine lmol/La 106 (45 to 276)
Albuminuria mg/24-hb 726 (122 to 4319)
Blood pressure mm Hg
Systolic 158 (19)
Diastolic 86 (10)
Hemoglobin A1c % 8.8 (1.6)
Serum cholesterol mmol/L 5.9 (1.5)
Hemoglobin mmol/L 8.7 (1.1)
Data are mean (SD).
aMedian (range); bgeometric mean (95% CI).
significantly associated with rate of decline in GFR, with
continuous variables separated in quintiles.
The impact of variables during the follow-up period
on the rate of decline in GFR was evaluated by mul-
tivariate regression analysis using mean values during
follow-up. This multivariate analysis revealed that higher
mean values of albuminuria, systolic blood pressure, and
hemoglobin A1c, lower values of hemoglobin, heavy
smoking, and presence of diabetic retinopathy during
follow-up, together with baseline age and baseline GFR
were significantly associated with an increased rate of
decline in kidney function (Table 2). Diastolic blood pres-
sure, pulse pressure, and cholesterol levels during follow-
up, gender and class of antihypertensive treatment for
more than 50% of the follow-up period (ACE inhibitor
or angiotensin II receptor blocker vs. other antihyper-
tensive agents) were not associated with rate of decline
in GFR and were excluded from the final model.
Among 23 patients without diabetic retinopathy at
the end of the study, the rate of decline in GFR was
only 2.6 (3.2) mL/min/1.73m2 compared with 5.5 (4.1)
mL/min/1.73m2 in the remaining patients (P < 0.001).
None of the potentially modifiable markers of in-
creased rate of decline in renal function either at baseline
or during follow-up showed a significant threshold, sug-
gesting that the best fit of the data is linear or curve linear.
Time to doubling in baseline serum creatinine or
development of ESRD
During follow-up, 63 (28%) of the patients doubled
their baseline serum creatinine, and 15 (7%) patients de-
veloped ESRD. The Cox proportional model revealed
that the following baseline variables predicted time to
the composite end point of doubling of serum creatinine
or development of ESRD: albuminuria, hemoglobin A1c,
systolic blood pressure, GFR, and baseline hemoglobin
(Table 3) Gender, age, known duration of diabetes or
nephropathy, degree of diabetic retinopathy, diastolic
blood pressure, pulse pressure, BMI, smoking, or serum
cholesterol were initially introduced in the model but
were subsequently excluded due to lack of statistical
significance.
To illustrate the individual influence of baseline albu-
minuria, hemoglobin A1c, systolic blood pressure, GFR,
and hemoglobin on doubling in serum creatinine or de-
velopment of ESRD, Kaplan-Meier curves are presented
on Figure 2, with baseline variables stratified into tertiles.
Cardiovascular disease and all-cause mortality
During follow-up of the 227 patients, new nonfatal car-
diovascular events including acute myocardial infarction
in 38 (17%) patients, stroke in 35 (15%), coronary artery
bypass grafts or percutaneous coronary intervention in 17
(7%), amputations in 13 (6%), and surgical intervention
for peripheral ischemia in 7 (3%) patients occurred.
During the follow-up period, 79 (35%) of the 227
patients died. Causes of death included cardiovascular
disease in 55 patients, ESRD in 14, cancer in 6, and
other various causes in 4 patients. Among the 79 pa-
tients who died during follow-up, the median (range)
survival time from entry to the study was 6.5 (3 to 16)
years. A Cox proportional hazard model revealed that
the following baseline variables influenced time to death
(all cause mortality): age, albuminuria, hemoglobin A1c,
and systolic blood pressure (Table 4). There was no sta-
tistical significance of gender, known duration of dia-
betes or nephropathy, degree of diabetic retinopathy,
diastolic blood pressure, pulse pressure, BMI, smoking,
hemoglobin, or serum cholesterol.
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Table 2. Baseline and follow-up variables associated with increased rate of decline in GFR in 227 type 2 diabetic patients with nephropathy
followed for 6.5 years
Variable Slope (95% CI) P value
Dependent variable
Rate of decline in GFR mL/min/year
Baseline model
Independent variables at baseline
Albuminuria log10 3.58 (2.22 to 4.9) <0.001
Systolic blood pressure per 10 mm Hg 0.33 (0.03 to 0.63) 0.02
Hemoglobin A1c per 1% 0.67 (0.32 to 1.02) <0.001
Age per 10 years 0.82 (0.01 to 1.58) 0.03
GFR per 10 mL/min/1.73 m2 0.60 (0.41 to 0.81) <0.001
Level of diabetic retinopathy nil/simplex/proliferative 1.64 (0.80 to 2.48) <0.001
R2 adjusted 0.24
Follow-up model
Independent variables
Mean albuminuria during follow-up log10 2.00 (0.92 to 3.10) <0.001
Mean systolic blood pressure during follow-up per 10 mm Hg 0.51 (0.14 to 0.88) 0.010
Mean hemoglobin A1c during follow-up per 1% 0.39 (0.01 to 0.77) 0.040
Mean hemoglobin during follow-up per mmol/L −0.70 (−1.34 to −0.07) 0.030
Diabetic retinopathy at end of follow-up present/absent 2.13 (0.49 to 3.77) 0.011
Smoking ≥20 cigarettes a day during follow-up yes/no 1.33 (0.01 to 2.64) 0.048
Baseline age per 10 years 0.77 (0.05 to 1.48) 0.035
Baseline GFR per 10 mL/min/1.73 m2 0.55 (0.33 to 0.75) <0.001
R2 adjusted 0.26
Variables excluded from the baseline model: gender, duration of diabetes and nephropathy, diastolic blood pressure, BMI, smoking, heavy smoking, serum cholesterol,
and hemoglobin. Variables excluded from the follow-up model: diastolic blood pressure and cholesterol levels during follow-up, gender, and class of antihypertensive
treatment.
An additional analysis of all 366 (257 males) type 2 di-
abetic patients with nephropathy and no known nondia-
betic renal disease revealed that 194 (53%) patients were
dead in 2003. The median (range) duration of follow-up
on survival was 6 (0 to 17) years in these 366 patients.
A Cox proportional hazard model revealed that baseline
age, albuminuria, hemoglobin A1c, and GFR influenced
time to death, whereas there was no statistical signifi-
cance impact of systolic blood pressure or other baseline
variables (data not shown).
DISCUSSION
In the present long-term prospective observational co-
hort study of 227 type 2 diabetic patients followed early
after the onset of nephropathy, we identified several mod-
ifiable variables including albuminuria, hemoglobin A1c,
systolic blood pressure, hemoglobin, and heavy smok-
ing to be independently associated with enhanced pro-
gression in renal disease, as evaluated by rate of decline
in GFR and by the time to doubling in baseline serum
creatinine or ESRD. Furthermore, baseline albuminuria,
hemoglobin A1c, and systolic blood pressure indepen-
dently predicted time to death, which was primarily due
to cardiovascular disease.
In order to obtain a valid determination of the rate
of decline in GFR, it has previously been suggested that
the applied GFR method should have good accuracy and
precision, repeated measurement should be performed
every 6 to 12 months, and the observation period should
extend at least two years [24]. These requirements were
met in our cohort consisting of all 227 Caucasian type 2
diabetic patients with nephropathy who were followed
with annual GFR measurements for at least three years.
Whereas at least three years of follow-up was required
to establish a valid rate of decline in renal function, this
requirement would bias mortality toward survivors due
to exclusion of patients who died before three years of
follow-up. Therefore, we performed an additional analy-
sis of baseline predictors of mortality, including all type
2 diabetic patients with nephropathy irrespective of the
duration of follow-up on renal function. In this cohort of
366 type 2 diabetic patients with nephropathy, baseline
age, albuminuria, hemoglobin A1c, and GFR were found
to have a significant impact on mortality. The impact of
age, albuminuria, and hemoglobin A1c on mortality was
similar to what was found among the 227 patients with at
least three years of follow-up on renal function.
Patients with clinical, laboratory, or biopsy-proven ev-
idence of nondiabetic nephropathy or urinary tract dis-
ease were excluded from our study. A clinical diagnosis of
diabetic nephropathy can be made in a patient with dia-
betes on the basis of persistent albuminuria, the presence
of diabetic retinopathy, and the absence of any clinical or
laboratory evidence of other kidney or urinary tract dis-
ease [1]. In type 2 diabetic patients with nephropathy, the
prevalence of biopsy proven nondiabetic nephropathies
varies from 5% to 30% depending on the enrollment
criteria of the patients [25–27]. The highest prevalence
of nondiabetic kidney disease has been documented
in patients lacking retinopathy. Underlying differences
in renal pathology among the studied patients may
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Fig. 1. Impact of baseline parameters: level of diabetic retinopathy, albuminuria, hemoglobin A1c, systolic blood pressure, glomerular filtration
rate (GFR), and age on the rate of decline in GFR (continuous variables are separated into quintiles). Crossed bars show the unadjusted association
with the rate of decline in GFR and solid bars show the adjusted association with rate of decline in GFR. Adjustment has been made for the other
five variables significantly associated with rate of decline in GFR.
Table 3. Baseline predictors of time to doubling of baseline serum
creatinine (to at least 177 lmol/L) or end-stage renal disease in 227
type 2 diabetic patients with nephropathy followed for 6.5 years (Cox
proportional hazard model)
Baseline Hazard ratio (95% CI) P value
Albuminuria log10 7.35 (3.35 to 15.70) <0.001
Systolic blood pressure per 1.23 (1.07 to 1.38) 0.001
10 mm Hg
HbA1c per 1% 1.48 (1.21 to 1.80) <0.001
Hemoglobin per 1 mmol/L 0.75 (0.57 to 0.98) 0.030
Baseline GFR per 10 mL/min 0.86 (0.74 to 0.96) <0.010
During follow-up, 63 (28%) of the patients doubled their baseline serum
creatinine, and 15 (7%) patients developed ESRD. The following baseline
variables were excluded due to lack of statistical significance: age, gender,
diabetes duration, diastolic blood pressure, BMI, serum cholesterol.
contribute to the variation in renal progression rates,
since biopsy studies of type 2 diabetic patients have
demonstrated a slower rate of decline in GFR in nondia-
betic nephropathies as compared to patients with diabetic
renal disease [28].
Studies of albuminuric patients with type 1 or type 2
diabetes not receiving early antihypertensive treatment
demonstrate that decline in GFR ranges from 10 to 14
mL/min/year [1, 8]. Our study demonstrates that early an-
tihypertensive treatment can reduce albuminuria and the
rate of decline in GFR (5.2 mL/min/year) in albuminuric
type 2 diabetic patients with rather well-preserved kid-
ney function, which confirms and extends findings in pre-
vious studies [4, 7, 9, 10, 29]. Even more importantly, our
data are in close agreement with the rate of GFR decline
reported in the angiotensin II receptor blocker group
of the Irbesartan Diabetic Nephropathy Trial (IDNT)
and Reduction of End Points in NIDDM with the An-
giotensin II Receptor Antagonist Losartan (RENAAL)
study: 5.5 mL/min/year and 4.4 mL/min/year, respectively
[16, 17].
We found that the degree of diabetic retinopathy at
baseline independently predicted the rate of decline
in GFR during follow-up. This was primarily due to a
very slow rate of decline in GFR in the relatively small
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Fig. 2. Kaplan-Meier curves of the percentage of patients with doubling in serum creatinine or end-stage renal disease (ESRD) during follow-up
stratified by tertiles of baseline: (A) albuminuria, (B) HbA1c, (C) systolic blood pressure, (D) GFR, and (E) hemoglobin.
Table 4. Baseline predictors of time to death (all-cause mortality) in
227 type 2 diabetic patients with nephropathy followed for 6.5 years
(Cox proportional hazard model)
Baseline Hazard ratio (95% CI) P value
Age per 10 years 1.82 (1.32 to 2.63) <0.001
Albuminuria log10 2.56 (1.34 to 4.88) <0.01
Systolic blood pressure 1.14 (1.00 to 1.29) 0.049
per 10 mm Hg
HbA1c per 1% 1.24 (1.05 to 1.47) <0.01
During follow-up a total 79 (35%) patients died. Causes of death included
cardiovascular disease in 55 patients, ESRD in 14, cancer in 6, and other various
causes in 4 patients. The following baseline variables were excluded due to lack
of statistical significance: age, gender, diabetes duration, diastolic blood pres-
sure, BMI, serum cholesterol, GFR, degree of retinopathy, smoking, hemoglobin.
subgroup of 23 patients who did not develop diabetic
retinopathy, whereas patients who developed diabetic
retinopathy during follow-up had a rate of decline in GFR
similar to patients with diabetic retinopathy present at
baseline. Our study has confirmed and extended the find-
ing from a recent study dealing with the impact of di-
abetic retinopathy on progression in kidney function in
albuminuric type 2 diabetic patients [9]. The greater rate
of decline in renal function in patients with increasing
severity of diabetic retinopathy may be explained by the
more severe renal lesions, since the degree of retinopathy
has been correlated to renal structural abnormalities and
functional impairment [10, 25, 30].
Albuminuria has previously been regarded as a marker
of the extent of glomerular damage, but experimen-
tal data suggest that proteinuria per se may contribute
to glomerular and tubulointerstitial lesions [31]. In our
study, baseline albuminuria was an independent predictor
for progression in renal disease, and the level of albumin-
uria during follow-up was independently associated with
the rate of decline in renal function which is in agreement
with previous findings in diabetic and nondiabetic renal
disease [3, 4, 11, 32–34]. When risk factors for progres-
sion in renal disease were evaluated in a post-hoc analysis
of 1513 patients with type 2 diabetes and impaired renal
function enrolled in RENAAL study, baseline albumin-
uria was the strongest and most consistent independent
risk factor for time to reach the composite end point of
doubling in serum creatinine or developing ESRD [13]. In
our study, the level of baseline albuminuria also predicted
increased all-cause mortality. Several studies have previ-
ously demonstrated increased all-cause mortality rates
with increasing levels of albuminuria, when comparing
patients with normo-, micro-, and macroalbuminuria, and
even slightly increased urinary albumin excretion rate
within the upper-normal range has been shown to be asso-
ciated with increased mortality rates [35, 36]. The excess
mortality is due to cardiovascular disease, and it has pre-
viously been suggested that the presence of albuminuria
Rossing et al: Nephropathy in type 2 diabetes 1603
is a marker of generalized vascular dysfunction leading
to increased atherosclerosis [37].
In type 2 diabetes, elevated blood pressure has previ-
ously been demonstrated to be an independent risk factor
for development and progression of diabetic nephropa-
thy, and several studies have demonstrated that anti-
hypertensive treatment reduces the risk of developing
nephropathy and slows the progression in renal injury
once nephropathy has developed [38]. Accordingly, re-
cent guidelines suggest an aggressive treatment of arte-
rial blood pressure with a target blood pressure of 130/80
mm Hg [39]. In our study, systolic but not diastolic blood
pressure was associated with increased progression in re-
nal disease, which is in accordance with previously pub-
lished data [4, 5, 9, 40]. This is likely due to the fact that
type 2 diabetic patients primarily suffer from isolated
systolic hypertension. In contrast to findings in a previ-
ous study of type 2 diabetic patients with nephropathy
and impaired renal function, diastolic blood pressure was
not negatively correlated to progression in renal disease
[40]. Furthermore, pulse pressure at baseline and during
follow-up did not have an independent effect on renal dis-
ease progression in our study of patients with rather well
preserved GFR. We could not demonstrate any specific
renoprotective effects by treatment with agents blocking
the renin-angiotensin system. However, our study was not
designed to evaluate treatment effects due to the risk of
confounding by indication in observational studies [41].
Randomized double-blind, clinical trials of type 2 dia-
betic patients with early or advanced renal disease have
clearly demonstrated specific renoprotective effects by
angiotensin II receptor blockers as compared with con-
ventional antihypertensive agents not blocking the renin-
angiotensin system [15–17].
Our study suggests an association between hyper-
glycemia and progression in renal disease, which we pre-
viously reported in 301 type 1 diabetic patients with di-
abetic nephropathy followed at Steno Diabetes Center
during the same time period [3]. In other studies of type
2 diabetic patients with nephropathy some reported a
correlation between hyperglycemia and increased renal
function loss [10, 29, 42], whereas other studies have not
found such an association [4, 5, 9, 11, 13]. The discrepancy
between the findings may in part be due to small sample
size, and consequently, lack of statistical power. One ex-
ception is the previously mentioned post-hoc analysis of
baseline predictors in the RENAAL trial, which did not
find any impact of baseline hemoglobin A1c on the time
to development of renal end points [13]. The discrepancy
in relation to our results may be because patients included
in the RENAAL study all had severe nephropathy with
reduced renal function at baseline, whereas patients in
our study were followed earlier in the course of renal
disease. Our study suggests that hyperglycemia plays a
role for the progression early in the course of nephropa-
thy, but it may be that the impact decreases over time
with deteriorating renal function when other risk factors
for progression, such as albuminuria and hypertension,
are more markedly increased and thus have a relatively
greater impact on renal outcome.
Smoking has previously been associated with an in-
creased risk of developing diabetic nephropathy [43–45].
In our study, we could not demonstrate a significant im-
pact of smoking on the rate of decline in GFR when
patients were stratified into smokers and nonsmokers.
However, when patients were stratified into heavy smok-
ers (smoking 20 cigarettes a day or more) and nonheavy
smokers (individuals smoking less than 20 cigarettes a
day and nonsmokers), heavy smokers had a significantly
greater rate of decline in GRF. This finding confirms and
extends the results from a study of 182 Japanese type 2
diabetic patients with nephropathy and impaired renal
function (>133 lmol/L), where smoking increased the
risk of progression to ESRD [11]. Smoking at baseline
was not a risk factor for renal outcome in the RENAAL
study [13]. However, the numbers of cigarettes smoked
was not quantified, and it was not taken into account
that some patients may have stopped smoking during
follow-up. Furthermore, a high cardiovascular mortality
was seen in the RENAAL study, and it is possible that
smokers may have been more likely to die of cardiovas-
cular disease before reaching the renal end points.
Anemia has been reported to be a frequent and un-
recognized companion to diabetes in particular when
nephropathy develops [46]. It has been suggested that
anemia occurs more frequently and develop earlier in di-
abetic compared to nondiabetic renal disease due to a
predominance of renal interstitium damage, systemic in-
flammation, and autonomic neuropathy in diabetic renal
disease [47]. Increased concern of the possible deleteri-
ous effects of hypoxia-induced organ damage in type 2
diabetic patients has been raised since the finding of an
increased risk of adverse renal outcome in patients with
even modest degrees of anemia [13]. In our study of pa-
tients with generally well-preserved kidney function at
inclusion, baseline hemoglobin even within the normal
range predicted time to doubling of serum creatinine or
ESRD independently of other risk factors including base-
line GFR, although baseline hemoglobin did not corre-
late to the subsequent rate of decline in GFR. Future
interventional studies of anemic patients with normal or
moderately reduced renal function is needed to establish
if anemia correction could retard progression in renal
disease or reduce the frequent occurrence of ischemic
cardiovascular disease.
In agreement with our findings, previous studies in type
2 diabetic patients have failed to demonstrate a significant
correlation between serum cholesterol and rate of decline
in GFR [4, 5, 11–13, 29]. In contrast, we have previously
demonstrated elevated cholesterol to be an independent
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risk factor for enhanced rate of decline in GFR in type 1
diabetic patients with nephropathy [3]. The lack of asso-
ciation between cholesterol and all-cause mortality in our
study may be due to the influence of other risk factors.
We did not find any significant impact of gender on
progression of renal disease or survival. Consequently,
the male preponderance seen in our study is not likely to
affect the generalizability of our data to populations with
a higher prevalence of females. The frequency of males in
our study is comparable to a cross-sectional study of uns-
elected type 2 diabetic patients attending another Danish
diabetes hospital, where 80% of patients with proteinuria
were male [48]. The male preponderance is in part due to
an unequal gender distribution among diabetic patients
in the Danish population, with more males than females
having diabetes [49]. Furthermore, male gender has been
demonstrated to be an independent risk factor for de-
velopment of incipient and overt diabetic nephropathy
[36].
Among the 227 patients included in our observational
study, 173 of the patients did not participate in any clinical
trials during the follow-up period. The remaining 54 of the
patients were enrolled in two different long-term clinical
intervention trials of two to three years’ duration at the
Steno Diabetes Center during the follow-up period. One
trial was comparing the renoprotective effects of ACE
inhibitors versus beta-blockers, the other trial compared
angiotensin II receptor blockers versus conventional an-
tihypertensive treatment. Consequently, it cannot be ex-
cluded that a Hawthorne effect (i.e., improved prognosis
due to participation in clinical trials irrespective of the
intervention) may have improved the outcome in these
patients. However, the rate of decline in GFR among pa-
tients participating in clinical trials was comparable to pa-
tients who were trial naı¨ve. This may in part be explained
by the relatively short duration of follow-up in the clini-
cal trial compared to the overall follow-up period of 6.5
years in the present study.
The available data suggest that multifactorial inter-
vention targeting blood pressure, albuminuria, hyper-
glycemia, smoking, hyperlipidemia, and, potentially, ane-
mia, is needed in order to improve the prognosis in type
2 diabetic patients with nephropathy. The success of such
a combined approach in delaying development and pro-
gression of micro- and macrovascular complications has
been demonstrated in microalbuminuric type 2 diabetic
patients [50, 51].
CONCLUSION
Our long-term prospective study of proteinuric type
2 diabetic patients has revealed several modifiable risk
factors for progression of renal disease, including al-
buminuria, hemoglobin A1c, systolic blood pressure,
hemoglobin, and heavy smoking. Furthermore, baseline
albuminuria, hemoglobin A1c, and systolic blood pres-
sure independently predicted time to death, which was
primarily due to cardiovascular disease.
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